(ASRNL) ASR Nederland - Ratings and Ratios
Insurance, Pensions, Mortgages, Asset Management, Health
Dividends
| Dividend Yield | 5.34% |
| Yield on Cost 5y | 13.19% |
| Yield CAGR 5y | 11.36% |
| Payout Consistency | 91.7% |
| Payout Ratio | 75.8% |
| Risk via 5d forecast | |
|---|---|
| Volatility | 23.5% |
| Value at Risk 5%th | 37.5% |
| Relative Tail Risk | -3.16% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 1.63 |
| Alpha | 34.64 |
| CAGR/Max DD | 0.99 |
| Character TTM | |
|---|---|
| Hurst Exponent | 0.547 |
| Beta | -0.007 |
| Beta Downside | 0.091 |
| Drawdowns 3y | |
|---|---|
| Max DD | 19.40% |
| Mean DD | 4.34% |
| Median DD | 3.06% |
Description: ASRNL ASR Nederland January 03, 2026
ASR Nederland N.V. (ASRNL) is a Dutch insurer offering a broad suite of insurance, pension, and mortgage products to individuals, entrepreneurs, and employers. Its operations are organized into five segments-Non-Life, Life, Asset Management, Distribution & Services, and Holding & Other-covering disability, health, property-casualty, pension, term life, funeral capital, and residential mortgage solutions under brands such as a.s.r., Aegon, Loyalis, TKP, and wijzeringeldzaken.
Key data points (as of FY 2023) include a combined ratio of 95.2% in the Non-Life segment, indicating underwriting profitability, and a Solvency II ratio of 213%, well above the regulatory minimum of 100%. The asset-management arm oversees roughly €30 bn in assets, with a growing allocation to renewable-energy real-estate (wind and solar farms) that aligns with the Netherlands’ 2030 climate targets. The Dutch mortgage market, where ASR holds ~5% market share, is sensitive to the European Central Bank’s policy rate; a 25 bp rate hike in Q4 2023 compressed net interest margins by 12 bps.
If you want to drill down into ASR’s valuation drivers and scenario-based risk metrics, the ValueRay platform provides a concise, data-rich view that can complement your own analysis.
Piotroski VR‑10 (Strict, 0-10) 5.0
| Net Income (1.56b TTM) > 0 and > 6% of Revenue (6% = 1.14b TTM) |
| FCFTA 0.04 (>2.0%) and ΔFCFTA 5.06pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| error: NWC/Revenue cannot be calculated (needs Current Assets/Liabilities and Revenue current+prev) |
| CFO/TA 0.04 (>3.0%) and CFO 5.37b > Net Income 1.56b (YES >=105%, WARN >=100%) |
| NO Net Debt/EBITDA fails (EBITDA <= 0) |
| error: Current Ratio cannot be calculated (needs Total Current Assets and Liabilities) |
| Outstanding Shares last Quarter (206.6m) change vs 12m ago -12.31% (target <= -2.0% for YES) |
| Gross Margin 100.1% (prev 96.71%; Δ 3.39pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 13.06% (prev 4.89%; Δ 8.17pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio -0.25 (EBITDA TTM -2.50b / Interest Expense TTM 2.74b) >= 6 (WARN >= 3) |
ValueRay F-Score (Strict, 0-100) 52.27
| 1. Piotroski 5.0pt |
| 2. FCF Yield 57.26% |
| 3. FCF Margin 27.95% |
| 4. Debt/Equity data missing |
| 5. Debt/Ebitda -2.41 |
| 6. ROIC - WACC (= -8.59)% |
| 7. RoE 16.73% |
| 8. Rev. Trend 45.03% |
| 9. EPS Trend -25.07% |
What is the price of ASRNL shares?
Over the past week, the price has changed by -1.11%, over one month by +2.58%, over three months by +4.60% and over the past year by +39.73%.
Is ASRNL a buy, sell or hold?
What are the forecasts/targets for the ASRNL price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 63 | 4% |
| Analysts Target Price | - | - |
| ValueRay Target Price | 77.5 | 28% |
ASRNL Fundamental Data Overview January 11, 2026
P/E Trailing = 13.3961
P/E Forward = 10.1215
P/S = 0.7815
P/B = 1.2701
Beta = 0.532
Revenue TTM = 19.05b EUR
EBIT TTM = -673.5m EUR
EBITDA TTM = -2.50b EUR
Long Term Debt = 9.52b EUR (from longTermDebt, last quarter)
Short Term Debt = unknown (none)
Debt = unknown
Net Debt = 6.03b EUR (from netDebt column, last quarter)
Enterprise Value = 9.30b EUR (12.79b + (null Debt) - CCE 3.49b)
Interest Coverage Ratio = -0.25 (Ebit TTM -673.5m / Interest Expense TTM 2.74b)
EV/FCF = 1.75x (Enterprise Value 9.30b / FCF TTM 5.33b)
FCF Yield = 57.26% (FCF TTM 5.33b / Enterprise Value 9.30b)
FCF Margin = 27.95% (FCF TTM 5.33b / Revenue TTM 19.05b)
Net Margin = 8.17% (Net Income TTM 1.56b / Revenue TTM 19.05b)
Gross Margin = 100.1% ((Revenue TTM 19.05b - Cost of Revenue TTM -19.0m) / Revenue TTM)
Gross Margin QoQ = 100.0% (prev 100.0%)
Tobins Q-Ratio = 0.07 (Enterprise Value 9.30b / Total Assets 141.01b)
Interest Expense / Debt = unknown (Interest Expense 1.95b / Debt none)
Taxrate = 20.28% (188.0m / 927.0m)
NOPAT = -536.9m (EBIT -673.5m * (1 - 20.28%)) [loss with tax shield]
Current Ratio = unknown (Total Current Assets 6.28b / Total Current Liabilities none)
Debt / Equity = unknown (Debt none)
Debt / EBITDA = -2.41 (negative EBITDA) (Net Debt 6.03b / EBITDA -2.50b)
Debt / FCF = 1.13 (Net Debt 6.03b / FCF TTM 5.33b)
Total Stockholder Equity = 9.31b (last 4 quarters mean from totalStockholderEquity)
RoA = 1.07% (Net Income 1.56b / Total Assets 141.01b)
RoE = 16.73% (Net Income TTM 1.56b / Total Stockholder Equity 9.31b)
RoCE = -3.58% (EBIT -673.5m / Capital Employed (Equity 9.31b + L.T.Debt 9.52b))
RoIC = -2.70% (negative operating profit) (NOPAT -536.9m / Invested Capital 19.88b)
WACC = 5.89% (E(12.79b)/V(12.79b) * Re(5.89%) + (debt-free company))
Discount Rate = 5.89% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 7.95%
Shares Correlation 3-Years: 100.0 | Cagr: 31.72%
[DCF Debug] Terminal Value 86.38% ; FCFF base≈5.33b ; Y1≈5.35b ; Y5≈5.72b
Fair Price DCF = 796.1 (EV 170.54b - Net Debt 6.03b = Equity 164.50b / Shares 206.6m; r=5.90% [WACC]; 5y FCF grow 0.0% → 2.90% )
EPS Correlation: -25.07 | EPS CAGR: -37.87% | SUE: 0.58 | # QB: 0
Revenue Correlation: 45.03 | Revenue CAGR: 30.79% | SUE: 3.35 | # QB: 4
EPS next Year (2026-12-31): EPS=5.72 | Chg30d=+0.065 | Revisions Net=-1 | Growth EPS=+6.0% | Growth Revenue=+3.3%